London Health Sciences Centre Research Institute

What London Health Sciences Centre Research Institute does

LHSCRI is the research institute of London Health Sciences Centre, a major academic teaching hospital in London, Ontario. Founded in 2003, it conducts translational clinical research in 13+ program areas including cancer, transplantation, nephrology, orthopaedics, surgery, mental health, imaging, neurology, cardiology, and personalized medicine. The institute spans multiple physical sites: a 22,500 sq ft CSTAR robotics facility at University Hospital, a 4,000 sq ft Kidney Clinical Research Unit at Victoria Hospital, the nearly 9,000 sq ft Matthew Mailing Centre for Translational Transplant Studies, the Children's Health Research Institute, and additional laboratory facilities. The research portfolio blends laboratory-based discovery with clinical trials, including flagship programs such as EpiSign™ (an AI-powered epigenetic diagnostic for 200+ genetic diseases), the LND101 fecal microbiota transplantation capsule program (active across melanoma, lung, and pancreatic cancer), Canada's largest implant retrieval collection (5,000+ specimens), and Canada's first clinical adoption of abdominal normothermic regional perfusion (A-NRP) for organ transplantation.

The institute's revenue model is grant- and foundation-driven rather than commercial: funding flows from provincial and federal healthcare allocations, competitive grants (Canadian Institutes of Health Research, Ontario Institute of Cancer Research, NCI), charitable foundations (Children's Health Foundation, London Health Sciences Foundation, Weston Family Foundation, Canadian Cancer Society, Move for Life Foundation, Hesch Foundation, St. Joseph's Health Care Foundation), industry-sponsored clinical trials (e.g., LUNA-2's $4M joint CCS/Weston backing), and donor bequests. Distribution is fully embedded in Ontario's publicly funded healthcare system, with trials and clinical integration delivered through LHSC's hospital network and partner institutions (Western University, Lawson Research Institute, Robarts Research Institute, CCTG). Patients constitute the primary downstream "customers," with clinician-scientists and academic collaborators as the principal upstream research partners.

Technically, LHSCRI operates a multi-disciplinary clinical and translational research infrastructure combining laboratory science, biorepositories (London Tumour Biobank), advanced imaging (PET/MRI, CT-RSA with weight-bearing CT at CenTRI, micro-CT for implant analysis), robotic surgery platforms (da Vinci), gait/biomechanics labs (Motek GRAIL), and AI/ML pipelines (EpiSign™, DISCOURSE in Psychosis NLP, computer vision for pancreatic and breast imaging, predictive ML for psychiatric treatment response). Sub-brands include Children's Health Research Institute (CHRI), the third largest hospital-based child and maternal health research institute in Canada. The organization is non-profit and privately classified, with no public ticker and no venture/PE ownership — it operates under the public healthcare and academic research ecosystem.

Name

London Health Sciences Centre Research Institute

Legal name

London Health Sciences Centre Research Institute

Website

https://lhscri.ca

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

10,001+ employees

Short description

LHSCRI is the research institute of London Health Sciences Centre in London, Ontario, conducting translational clinical research across cancer, transplantation, nephrology, surgery, and personalized medicine, serving patients of LHSC and academic collaborators through clinical trials and AI-enabled diagnostics like EpiSign™ and LND101 FMT capsules.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAEAB

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAGAEAI

Sample Logistics, Biorepository & IVD Kit Management (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAAALAI

Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

Keywords

• Clinical research
• Translational research
• Hospital-based research
• Clinical trials
• Cancer research

Headquarters

HQ city

London

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Government and Healthcare System Funding: Research institute funded primarily through government healthcare funding, Ontario Health, and healthcare system allocations as part of London Health Sciences Centre's research mandate.
2. Research Grants and Foundations: Funded through competitive research grants from agencies including Canadian Institutes of Health Research, Ontario Institute of Cancer Research, as well as charitable foundations such as Children's Health Foundation, London Health Sciences Foundation, Weston Family Foundation, and Move for Life Foundation.
3. Clinical Trial Revenue: Revenue generated through conducting clinical trials funded by organizations such as Canadian Cancer Society, Weston Family Foundation, and industry sponsors. The LUNA-2 trial received $4 million joint investment from CCS and Weston Family Foundation.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

London Health Sciences Centre Research Institute (LHSCRI) operates as a hospital-based clinical and translational research institute embedded within London Health Sciences Centre. It delivers investigator-initiated and sponsored clinical trials, multi-disease research programs (cancer, transplantation, nephrology, surgery, mental health, orthopaedics, critical illness, imaging, personalized medicine), specialized biobanks and core facilities (Kidney Clinical Research Unit, CSTAR robotics, Implant Retrieval Laboratory, London Tumour Biobank), and proprietary diagnostics such as EpiSign™ and LND101 fecal microbiota transplantation capsules.

Product overview

London Health Sciences Centre Research Institute (LHSCRI) operates as a comprehensive healthcare research institute rather than a traditional product company. Its portfolio consists of specialized research programs, clinical trial units, diagnostic technologies, and treatment innovations. Core offerings include the Cancer Research Laboratory Program with translational units for breast, ovarian, and gastrointestinal cancers; the Baker Centre for Pancreatic Cancer with organoid facility; EpiSign™ AI-powered genetic diagnostic technology; LND101 fecal microbiota transplantation capsules; and the Matthew Mailing Centre for Transplant Studies. Supporting infrastructure includes the 4,000 sq ft Kidney Clinical Research Unit (KCRU) managing 70+ active studies, the 22,500 sq ft CSTAR robotics facility, and the Children's Health Research Institute (CHRI) with three research divisions. The institute also houses the PTSD Research Unit and pharmacogenomics program that has influenced clinical standards for over 10,000 patients. Research programs span cancer, transplantation, cardiology, neurology, orthopaedics, mental health, imaging, and critical illness, with technology platforms including AI/ML-based diagnostics, robotics-assisted surgery, and advanced imaging systems.

Differentiator

Problem solved

Functional benefit

Brands

• Children's Health Research Institute (CHRI): A program of LHSCRI focused on discovering ways to prevent and treat diseases affecting babies, children and youth. It includes three divisions: Children's Health and Therapeutics, Maternal Fetal and Newborn Health, and Genetics and Development.

Products and services

• Cancer Research Laboratory Program (CRLP) A translational science program within LHSCRI that investigates cancer biology across laboratory and clinical settings to identify cancer behaviour and enhance treatment, serving cancer patients at LHSC.
• Baker Centre for Pancreatic Cancer A specialized clinical-research centre at LHSC providing elevated, fast-tracked pancreatic cancer care with access to investigational treatments and integrating laboratory-based science, clinical research, and a Pan-cancer Organoid Facility.
• Matthew Mailing Centre for Translational Transplant Studies A nearly 9,000-square-foot world-class transplant research facility within LHSCRI that accelerates translation of laboratory discoveries into transplant patient care under Dr. Anthony Jevnikar.
• Lilibeth Caberto Kidney Clinical Research Unit (KCRU) A 4,000 square-foot clinical research facility within LHSCRI dedicated to kidney health and disease research, including dialysis and transplantation, coordinating more than 70 active clinical research studies.
• Canadian Surgical Technologies and Advanced Robotics (CSTAR) A 22,500 square-foot research and education facility within LHSCRI that researches, develops, and tests minimally invasive surgical technologies and robotics, including AI-based systems and extended-reality platforms.
• EpiSign™ Diagnostic Technology An AI-powered diagnostic technology developed at LHSCRI that analyzes a patient's epigenome to diagnose more than 200 genetic diseases and identify biomarkers for non-genetic conditions, informing care for patients with rare diseases.
• LND101 Fecal Microbiota Transplantation Capsules Fecal microbiota transplantation capsules processed from healthy donor stool, developed at Lawson Research Institute and tested in LHSCRI-led clinical trials to restore gut microbiome and improve response to immunotherapy in melanoma, pancreatic, kidney and lung cancer patients.
• Paediatric Haematology Oncology Research Group (PHORG) An LHSCRI research team advancing treatments and survivorship for paediatric cancers through clinical trials in neuroblastoma, Wilms tumours, CNS germinomas and gliomas, in collaboration with the Children's Oncology Group.
• London Tumour Biobank An LHSCRI-affiliated biorepository collecting tumour tissue, blood and urine samples from breast and prostate biopsy patients, providing researchers with samples and comprehensive clinical data for cancer research.
• Post-Traumatic Stress Disorder (PTSD) Research Unit An LHSCRI research unit dedicated to understanding brain mechanisms underlying PTSD, identifying PTSD subtypes, and developing innovative brain-guided mind-body treatments for traumatized populations.
• Children's Health Research Institute (CHRI) A program of LHSCRI and the third-largest hospital-based child and maternal health research institute in Canada, with divisions in Children's Health and Therapeutics, Maternal/Fetal/Newborn Health, and Genetics and Development, serving paediatric and maternal health research.
• Pharmacogenomics Program An LHSCRI personalized-medicine program that uses pharmacogenomics to tailor drug therapies, having helped tailor drug therapies for over 10,000 patients and influenced Ontario Health's approval of DPD testing as standard of care.
• A-NRP Organ Preservation and Transplantation Program An LHSCRI transplant program offering the first-in-Canada abdominal normothermic regional perfusion (A-NRP) technique to optimize organs from donors after circulatory death, enabling successful transplantation of kidneys and livers at LHSC.

Quantifiable outcome

• 80% response rate in lung cancer patients receiving FMT with immunotherapy vs 39-45% for immunotherapy alone
• +4 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability13 records

Feature8 records

Partnerships

20 partnerships are on record, tiered core, supporting and major.

• Lawson Research Institute (St. Joseph's Health Care London)coreStrategic or Co-development PartnerClose collaborative partnership for conducting clinical trials and translational research. LHSCRI and Lawson work together on FMT capsule research for cancer treatment, with Lawson producing the capsules and LHSCRI overseeing patient care in clinical trials.
• Western UniversitycoreStrategic or Co-development PartnerAcademic partnership with Schulich School of Medicine & Dentistry and other faculties. Many LHSCRI scientists hold cross-appointments with Western University, enabling joint research programs and training.
• Robarts Research InstitutecoreStrategic or Co-development PartnerCollaboration on imaging research, including Centre for Translational Radiographic Imaging (CenTRI). The first 3D metal printer in a North American medical school is located at Robarts, enabling patient-specific implant design and fabrication.
• Fowler-Kennedy Sports Medicine ClinicsupportingStrategic or Co-development PartnerCollaborates on orthopaedic surgery research including randomized controlled trials. Home to Wolf Orthopaedic Biomechanics Laboratory (WOBL) for joint biomechanics studies.
• Canadian Cancer Trials Group (CCTG)majorStrategic or Co-development PartnerNational clinical trial group administering the LUNA-2 trial nationally across Canada. Led by researchers at LHSCRI and Lawson.
• ICEScoreStrategic or Co-development PartnerIndependent not-for-profit research institute providing population-based health information. LHSCRI scientists hold appointments at ICES for kidney, dialysis and transplant research.
• Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM)majorStrategic or Co-development PartnerCollaboration on Phase II lung and melanoma FMT clinical trials. CRCHUM led by researchers including Dr. Arielle Elkrief and Dr. Rahima Jamal.
• Ontario Health (Trillium Gift of Life Network)coreStrategic or Co-development PartnerProvincial partner for organ donation and transplantation. Approved A-NRP technique for transplant surgeries in Ontario and provides ongoing support for transplant research.
• Children's Oncology Group (COG)majorStrategic or Co-development PartnerInternational paediatric cancer research consortium. PHORG team contributes to large-scale, multi-centre trials including those that led to approval of blinatumomab immunotherapy.
• Canadian RSA NetworksupportingStrategic or Co-development PartnerMulti-centre clinical trials network for evaluating new implants using radiostereometric analysis (RSA) x-ray technology.
• Canadian Surgical Technologies & Advanced Robotics (CSTAR)coreStrategic or Co-development PartnerPremier research and education program at LHSC focusing on minimally invasive surgical technologies and robotics, located within Lindros Legacy Research Pavilion.
• Thames Valley Children's CentresupportingStrategic or Co-development PartnerPartner in Children's Health Research Institute alongside LHSCRI and Western University, contributing to child health research.
• Centre for Research on Social InequalitysupportingStrategic or Co-development PartnerLocated in Department of Sociology at Western University, providing networking opportunities with social science and population health researchers for children's health research.
• Paediatric Oncology Group of Ontario (POGO)supportingStrategic or Co-development PartnerPaediatric oncology research network. PHORG team manages the childhood cancer database containing all Ontario paediatric cancer patient information as POGO's London site.
• Western Bone and Joint InstitutesupportingStrategic or Co-development PartnerCollaborative research partnership for orthopaedic research alongside LHSCRI's active group of surgeons, scientists and engineers.
• Facility for Biomedical Device Design and FabricationsupportingStrategic or Co-development PartnerLocated at Robarts Research Institute at Western University, houses first 3D metal printer in a North American medical school for patient-specific implants.
• Canadian Pharmacogenomics Network on Drug SafetysupportingStrategic or Co-development PartnerNational network connected through researchers focusing on personalized medicine at LHSCRI.
• Sepsis CanadasupportingStrategic or Co-development PartnerNational consortium of sepsis researchers. Sepsis group within CCIR are members contributing to research and training.
• National Preclinical Sepsis Platform consortiumsupportingStrategic or Co-development PartnerNational consortium providing sepsis-related training through LifTING and Sepsis Canada Research Training Program.
• Biomedical Imaging Research Centre (BIRC)coreStrategic or Co-development PartnerWestern University centre providing access to latest 3T MRI, PET/MRI, and CT scanners for imaging research.

Scale indicators15 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sunnybrook Research Institute: Research arm of Sunnybrook Health Sciences Centre with comparable programs in cancer, imaging, and surgical technologies. Comparable hospital-embedded translational model in Ontario.
• Ottawa Hospital Research Institute (OHRI): Hospital-affiliated research institute with similar translational and clinical-trials infrastructure, including strong programs in cancer, transplantation, and personalized medicine. Direct competitor for CIHR and provincial funding.
• Keenan Research Centre for Biomedical Science (St. Michael's Hospital): Hospital-based research institute in Ontario with overlapping strengths in critical illness, transplantation, and clinical trials; comparable scale and funding sources.
• Lawson Research Institute (St. Joseph's Health Care London): Sister hospital-based research institute in London, Ontario, formally partnered with LHSCRI on FMT capsule research and clinical trials. Operates the same translational model and shares investigators and patients.
• BC Cancer Research Centre: Major Canadian cancer research centre with biorepositories, clinical trials, and translational programs. Most directly comparable on the oncology, biobanking, and clinical-trial dimensions.
• Robarts Research Institute (Western University): Western University-affiliated medical research institute co-located in London, collaborating with LHSCRI on imaging (CenTRI), 3D-printed implants, and translational programs. Closest physical and operational peer.
• Toronto General Hospital Research Institute (University Health Network): One of Canada's largest hospital-based research institutes embedded in a major academic hospital. Competes for transplant, oncology, and multi-organ research grants and talent in the same Canadian ecosystem.
• McGill University Health Centre Research Institute (RI-MUHC): Quebec hospital-based research institute with multi-disciplinary clinical and translational programs (cancer, cardiovascular, respiratory). Comparable scale and CIHR-funded research mix.

Regional players

• Children's Hospital of Eastern Ontario Research Institute (CHEO RI): Paediatric hospital research institute in Ottawa with comparable maternal-child research scope to LHSCRI's Children's Health Research Institute; serves an overlapping Ontario paediatric mandate.

Broad incumbents

• Ontario Institute for Cancer Research (OICR): Provincial funder and translational cancer research organization; provides grants to LHSCRI's kidney cancer FMT trial and runs province-wide cancer research programs across multiple sites.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/playlist?list=PL7oyqNL0YrTojnGTvP7RlmIqd6V06Nsxj
• Facebookfacebook.com/LHSCRI
• LinkedInlinkedin.com/company/london-health-sciences-centre-research-institute
• Instagraminstagram.com/LHSCRI
• Xx.com/lhscri

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about London Health Sciences Centre Research Institute